Discovery and optimization of a novel series of Dyrk1B kinase inhibitors to explore a MEK resistance hypothesis.

Kettle, Jason G; Ballard, Peter; Bardelle, Catherine; Cockerill, Mark; Colclough, Nicola; Critchlow, Susan E; Debreczeni, Judit; Fairley, Gary; Fillery, Shaun; Graham, Mark A; Goodwin, Louise; Guichard, Sylvie; Hudson, Kevin; Ward, Richard A; Whittaker, David

Kettle, Jason G; Ballard, Peter; Bardelle, Catherine; Cockerill, Mark; Colclough, Nicola; Critchlow, Susan E; Debreczeni, Judit; Fairley, Gary; Fillery, Shaun; Graham, Mark A; Goodwin, Louise; Guichard, Sylvie; Hudson, Kevin; Ward, Richard A; Whittaker, David.

Afiliación

Kettle JG; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Ballard P; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Bardelle C; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Cockerill M; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Colclough N; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Critchlow SE; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Debreczeni J; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Fairley G; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Fillery S; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Graham MA; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Goodwin L; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Guichard S; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Hudson K; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Ward RA; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.
Whittaker D; Oncology iMed, AstraZeneca, Alderley Park, Macclesfield, SK10 4TG, United Kingdom.

J Med Chem ; 58(6): 2834-44, 2015 Mar 26.

Article en En | MEDLINE | ID: mdl-25738750

Asunto(s)

Inhibidores de Proteínas Quinasas/química; Inhibidores de Proteínas Quinasas/farmacología; Proteínas Serina-Treonina Quinasas/antagonistas & inhibidores; Proteínas Tirosina Quinasas/antagonistas & inhibidores; Animales; Células COS; Línea Celular Tumoral; Chlorocebus aethiops; Descubrimiento de Drogas; Resistencia a Medicamentos; Humanos; Quinasas Quinasa Quinasa PAM/antagonistas & inhibidores; Quinasas Quinasa Quinasa PAM/metabolismo; Modelos Moleculares; Inhibidores de Proteínas Quinasas/farmacocinética; Proteínas Serina-Treonina Quinasas/química; Proteínas Serina-Treonina Quinasas/genética; Proteínas Serina-Treonina Quinasas/metabolismo; Proteínas Tirosina Quinasas/química; Proteínas Tirosina Quinasas/genética; Proteínas Tirosina Quinasas/metabolismo; Interferencia de ARN; ARN Interferente Pequeño/genética; Ratas Wistar; Quinasas DyrK

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Proteínas Tirosina Quinasas / Proteínas Serina-Treonina Quinasas / Inhibidores de Proteínas Quinasas Límite: Animals / Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2015 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google